Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center Identifier:
First received: October 4, 2000
Last updated: December 7, 2011
Last verified: December 2011

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.

Condition Intervention Phase
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Biological: anti-thymocyte globulin
Biological: graft-versus-tumor induction therapy
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Lymphosarcoma B-cell Lymphoma Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia Multiple Myeloma Myeloid Leukemia Acute Myeloid Leukemia Acute Non Lymphoblastic Leukemia Mycosis Fungoides Hodgkin Lymphoma Lymphoma, Large-cell Anaplastic Large Cell Lymphoma Lymphoblastic Lymphoma Acute Lymphoblastic Leukemia Myelofibrosis Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Waldenstrom Macroglobulinemia Monoclonal Gammopathy of Undetermined Significance Diffuse Large B-Cell Lymphoma Follicular Lymphoma Burkitt Lymphoma Chronic Myeloid Leukemia Anaplastic Plasmacytoma Aplastic Anemia Essential Thrombocythemia Polycythemia Vera Childhood Acute Lymphoblastic Leukemia Mantle Cell Lymphoma Cutaneous T-cell Lymphoma Chronic Myeloproliferative Disorders Leukemia, T-cell, Chronic Acute Erythroid Leukemia Sezary Syndrome AL Amyloidosis Myelodysplastic/myeloproliferative Disease Plasmablastic Lymphoma Lymphoma, Large-cell, Immunoblastic Juvenile Myelomonocytic Leukemia Angioimmunoblastic T-cell Lymphoma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Adult T-cell Leukemia/lymphoma Hodgkin Lymphoma, Childhood Acute Megakaryoblastic Leukemia Di Guglielmo's Syndrome Small Intestine Cancer Chronic Neutrophilic Leukemia
U.S. FDA Resources

Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Evaluation of Donor Engraftment [ Time Frame: at 28 days ] [ Designated as safety issue: No ]
    Peripheral blood from the donor and patient is obtained for chimerism studies. The primary analysis will consist of estimating the graft failure proportions for each of the separate patient groups and calculating confidence intervals for these proportions. This analysis will be done conditional on patients surviving at least 28 days.

Secondary Outcome Measures:
  • Stable donor hematopoietic chimerism [ Time Frame: at day 100 ] [ Designated as safety issue: No ]
    Number of Patients Transplanted More Than 100 Days Ago

  • Event free and overall survival [ Time Frame: to progression/death ] [ Designated as safety issue: No ]

Enrollment: 58
Study Start Date: June 2000
Study Completion Date: October 2011
Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: anti-thymocyte globulin
    anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
    Biological: graft-versus-tumor induction therapy
    Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
    Drug: cyclophosphamide
    cyclophosphamide IV over 2 hours on days -3 to -2
    Drug: fludarabine phosphate
    fludarabine IV over 30 minutes on days -8 to -4
    Procedure: peripheral blood stem cell transplantation
    Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
Detailed Description:


  • Determine the rates of durable full donor hematologic engraftment in patients with high-risk hematologic malignancies or severe aplastic anemia treated with non-myeloablative conditioning using fludarabine, cyclophosphamide, and anti-thymocyte globulin followed by allogeneic peripheral blood stem cell transplantation.
  • Determine the acute and delayed toxic effects of this non-myeloablative conditioning regimen in this patient population.
  • Determine the event-free and overall survival of patients treated with this regimen.
  • Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen.
  • Determine the rate and quality of immune reconstitution in patients treated with this regimen.
  • Determine the rate of disease relapse and incidence of post-transplantation lymphoproliferative disease in these patients.

OUTLINE: Patients are stratified according to disease category (malignant vs non-malignant) and graft source (unrelated vs HLA-matched sibling).

Beginning at least 4 weeks after conventional-dose chemotherapy, patients receive non-myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and anti-thymocyte globulin IV over at least 4 hours on days -2 and -1. Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Patients are followed weekly for 3 months, every 2 weeks for 3 months, monthly for 6 months, and then every 2 months thereafter.

PROJECTED ACCRUAL: A minimum of 30 patients will be accrued for this study within 4 years.


Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically proven high-risk hematologic malignancy

    • Acute non-lymphocytic leukemia (ANLL) after induction failure, or in first complete remission (CR) with high-risk features, including any of the following:

      • Stem cell or biphenotypic classification (AML-M0)
      • Erythroleukemia (AML-M6)
      • Acute megakaryocytic leukemia (AML-M7)
      • Cytogenetic markers indicative of poor prognosis
      • Failure to achieve CR after standard induction therapy
    • Acute lymphocytic leukemia (ALL) or ANLL in relapse or second or subsequent remission
    • Chronic myelogenous leukemia (CML) in chronic or accelerated phase

      • Patients with CML in blast crisis are eligible after reinduction chemotherapy places them in chronic phase
    • High-risk ALL in first CR with high risk defined by presence of t(4;11), t(9;22) translocation, hyperleukocytosis (initial WBC greater than 30,000/mm^3), or failure to achieve CR by day 28 after standard induction

      • No T-cell ALL or t(8;14) positive B-cell ALL in first remission with hyperleukocytosis
    • Myelodysplastic syndrome by peripheral blood smear and bone marrow examination

      • Refractory to medical management OR
      • Cytogenetic abnormalities predictive of transformation into acute leukemia including 5q-, 7q-, monosomy 7, and trisomy 8 OR
      • Evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)
    • Multiple myeloma, non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after autologous stem cell transplantation (SCT)

      • At least 3 months since prior autologous SCT
    • Hodgkin's lymphoma, NHL, or multiple myeloma beyond first CR or primary induction failures whose disease has demonstrated sensitivity to pre-transplantation cytoreduction (defined as greater than 50% reduction in tumor burden)

      • Mantle zone NHL allowed after induction therapy
    • Myeloproliferative disorder that is non-responsive to medical management and requires allografting, unless evidence of grade 3 or worse myelofibrosis on marrow biopsy OR
  • Histologically proven acquired severe aplastic anemia (SAA) that is recurrent or unresponsive after anti-thymocyte globulin and/or cyclosporine

    • SAA defined by at least 2 of the following conditions:

      • Granulocyte count less than 500/mm^3
      • Platelet count less than 20,000/mm^3
      • Absolute reticulocyte count less than 20,000/mm^3 after correction for hematocrit
  • Ineligible for full ablative conditioning due to any of the following conditions:

    • Prior extensive therapy (more than 2 salvage chemotherapy regimens and/or autologous transplantation)
    • Over age 55 OR
    • Under age 55 with comorbid disease (e.g., suboptimal cardiac, pulmonary, or renal function and/or prior life-threatening infection)
  • HLA-A, B, and DR phenotypically identical sibling donor OR
  • HLA-A, B, and DR identical genetically matched unrelated donor
  • No ANLL in first CR (less than 5% blasts in marrow) with translocations t(8;21) and inv(16) unless failed first-line induction therapy OR
  • No ANLL in first CR (less than 5% blasts in marrow) with translocations t(15;17) abnormality unless failed first-line induction therapy OR molecular evidence of persistent disease
  • No active CNS disease



  • 0 to 70

Performance status:

  • Zubrod 0-1
  • Karnofsky 80-100%

Life expectancy:

  • At least 3 months


  • See Disease Characteristics


  • ALT/AST no greater than 4 times normal
  • Bilirubin no greater than 2.0 mg/dL


  • See Disease Characteristics
  • Creatinine clearance at least 50 mL/min


  • See Disease Characteristics
  • Shortening fraction or ejection fraction at least 40% of normal for age by echocardiogram or radionuclide scan
  • No clinically significant comorbid illnesses (e.g., myocardial infarction or cerebrovascular accident)


  • See Disease Characteristics
  • FVC and FEV_1 at least 60% of predicted for age
  • DLCO at least 60% of predicted for adults


  • No severe neurosensory symptoms (i.e., peripheral neuropathy)
  • HIV negative
  • Active infection allowed if controlled by appropriate drug therapy
  • Not pregnant or nursing
  • Negative pregnancy test


Biologic therapy:

  • See Disease Characteristics


  • See Disease Characteristics

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • Recovered from prior therapy
  • No concurrent investigational agents unless approved by protocol investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006379

United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Tamila Kindwall-Keller, DO Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  More Information

Responsible Party: Case Comprehensive Cancer Center Identifier: NCT00006379     History of Changes
Other Study ID Numbers: CWRU3Y00  P30CA043703  CWRU-3Y00  05-00-07  NCI-G00-1868 
Study First Received: October 4, 2000
Last Updated: December 7, 2011
Health Authority: United States: Federal Government

Keywords provided by Case Comprehensive Cancer Center:
monoclonal gammopathy of undetermined significance
recurrent childhood acute lymphoblastic leukemia
recurrent adult Hodgkin lymphoma
recurrent cutaneous T-cell non-Hodgkin lymphoma
isolated plasmacytoma of bone
extramedullary plasmacytoma
refractory multiple myeloma
Waldenstrom macroglobulinemia
recurrent childhood lymphoblastic lymphoma
recurrent childhood acute myeloid leukemia
recurrent adult acute myeloid leukemia
recurrent adult acute lymphoblastic leukemia
relapsing chronic myelogenous leukemia
small intestine lymphoma
chronic phase chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
adult acute myeloid leukemia in remission
adult acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood acute lymphoblastic leukemia in remission
polycythemia vera
chronic idiopathic myelofibrosis
essential thrombocythemia
adult acute erythroid leukemia (M6)
adult acute megakaryoblastic leukemia (M7)
childhood acute erythroleukemia (M6)
childhood acute megakaryocytic leukemia (M7)
recurrent/refractory childhood Hodgkin lymphoma
refractory anemia with excess blasts

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Myeloproliferative Disorders
Precancerous Conditions
Myelodysplastic-Myeloproliferative Diseases
Intestinal Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms processed this record on October 26, 2016